Dianthus Therapeutics (DNTH) Cash & Equivalents (2017 - 2025)
Historic Cash & Equivalents for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $56.0 million.
- Dianthus Therapeutics' Cash & Equivalents rose 6626.77% to $56.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 6626.77%. This contributed to the annual value of $22.8 million for FY2024, which is 8277.57% down from last year.
- According to the latest figures from Q3 2025, Dianthus Therapeutics' Cash & Equivalents is $56.0 million, which was up 6626.77% from $13.2 million recorded in Q2 2025.
- Dianthus Therapeutics' 5-year Cash & Equivalents high stood at $329.7 million for Q1 2024, and its period low was $10.1 million during Q1 2025.
- In the last 4 years, Dianthus Therapeutics' Cash & Equivalents had a median value of $40.3 million in 2023 and averaged $87.4 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 132048.94% in 2024, then crashed by 9693.2% in 2025.
- Dianthus Therapeutics' Cash & Equivalents (Quarter) stood at $15.4 million in 2022, then skyrocketed by 761.21% to $132.3 million in 2023, then crashed by 82.78% to $22.8 million in 2024, then surged by 145.63% to $56.0 million in 2025.
- Its Cash & Equivalents stands at $56.0 million for Q3 2025, versus $13.2 million for Q2 2025 and $10.1 million for Q1 2025.